These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 1722167)

  • 1. 5 alpha-metabolism in finasteride-treated subjects and male pseudohermaphrodites with inherited 5 alpha-reductase deficiency. A review.
    Imperato-McGinley J
    Eur Urol; 1991; 20 Suppl 1():78-81. PubMed ID: 1722167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C19 and C21 5 beta/5 alpha metabolite ratios in subjects treated with the 5 alpha-reductase inhibitor finasteride: comparison of male pseudohermaphrodites with inherited 5 alpha-reductase deficiency.
    Imperato-McGinley J; Shackleton C; Orlic S; Stoner E
    J Clin Endocrinol Metab; 1990 Mar; 70(3):777-82. PubMed ID: 1689740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity.
    Imperato-McGinley J; Gautier T; Cai LQ; Yee B; Epstein J; Pochi P
    J Clin Endocrinol Metab; 1993 Feb; 76(2):524-8. PubMed ID: 8381804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.
    McConnell JD; Wilson JD; George FW; Geller J; Pappas F; Stoner E
    J Clin Endocrinol Metab; 1992 Mar; 74(3):505-8. PubMed ID: 1371291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical development of a 5 alpha-reductase inhibitor, finasteride.
    Stoner E
    J Steroid Biochem Mol Biol; 1990 Nov; 37(3):375-8. PubMed ID: 1701660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
    Habib FK; Ross M; Tate R; Chisholm GD
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged treatment with finasteride (a 5 alpha-reductase inhibitor) does not affect bone density and metabolism.
    Matzkin H; Chen J; Weisman Y; Goldray D; Pappas F; Jaccard N; Braf Z
    Clin Endocrinol (Oxf); 1992 Nov; 37(5):432-6. PubMed ID: 1283117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group.
    Stoner E
    J Urol; 1992 May; 147(5):1298-302. PubMed ID: 1373779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia.
    Beisland HO; Binkowitz B; Brekkan E; Ekman P; Kontturi M; Lehtonen T; Lundmo P; Pappas F; Round E; Shapiro D
    Eur Urol; 1992; 22(4):271-7. PubMed ID: 1283370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
    Gormley GJ; Stoner E; Bruskewitz RC; Imperato-McGinley J; Walsh PC; McConnell JD; Andriole GL; Geller J; Bracken BR; Tenover JS
    N Engl J Med; 1992 Oct; 327(17):1185-91. PubMed ID: 1383816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
    Bartsch G; Rittmaster RS; Klocker H
    Urologe A; 2002 Sep; 41(5):412-24. PubMed ID: 12426858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Finasteride for benign prostatic hyperplasia.
    Hasinski S; Miller JL; Rose LI
    Am Fam Physician; 1992 Nov; 46(5):1511-4. PubMed ID: 1279965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal effects of a 5 alpha-reductase inhibitor (finasteride) on hormonal levels in normal men and in patients with benign prostatic hyperplasia.
    Vermeulen A; Giagulli VA; De Schepper P; Buntinx A
    Eur Urol; 1991; 20 Suppl 1():82-6. PubMed ID: 1722168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of finasteride in men with benign prostatic hyperplasia.
    Walsh PC
    J Urol; 1993 Apr; 149(4):932-3. PubMed ID: 7681121
    [No Abstract]   [Full Text] [Related]  

  • 17. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group.
    Prostate; 1993; 22(4):291-9. PubMed ID: 7684524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
    Geller J
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dutasteride: a potent dual inhibitor of 5-alpha-reductase for benign prostatic hyperplasia.
    Rabasseda X
    Drugs Today (Barc); 2004 Aug; 40(8):649-61. PubMed ID: 15510237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study.
    Kirby RS; Vale J; Bryan J; Holmes K; Webb JA
    Eur Urol; 1993; 24(1):20-6. PubMed ID: 7689971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.